Joseph Tuscano

Clinical trials

• Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

  Principal investigator · Recruiting · Phase 2

  University of California, Davis

  2025–2029
• Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  Principal investigator · Recruiting · Phase 1

  National Cancer Institute (NCI)

  2024–2027
• The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors

  Principal investigator · Suspended · Phase 1

  University of California, Davis

  2023–2027
• Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

  Principal investigator · Recruiting · Phase 2

  University of California, Davis

  2023–2027